trending Market Intelligence /marketintelligence/en/news-insights/trending/lgQuAtZH6ZiGpBArFoH36g2 content esgSubNav
In This List

PhaseBio Pharmaceuticals appoints director

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


PhaseBio Pharmaceuticals appoints director

PhaseBio Pharmaceuticals Inc. appointed Edmund Harrigan to its board, effective Dec. 13.

Harrigan is also a board member of Bellicum Pharmaceuticals Inc., Karuna Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc. and Lyndra Therapeutics.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat orphan diseases.